The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
复制标题
DOI：
10.1155/2012/271028
复制
发表时间：
2012
影响因子：
--
通讯作者：
Rocic P
中科院分区：
文献类型：
--
作者：
Hutcheson R;Rocic P
代谢综合征影响着 30% 的美国人口，且患病率不断增加。在本文中，我们探讨了代谢综合征与一般心血管疾病，特别是冠状动脉疾病（CAD）的发病率和严重程度之间的关系。此外，我们还研究了代谢综合征对冠状动脉血运重建治疗（包括 CABG、PTCA 和冠状动脉侧枝发育）结果的影响。我们还研究了代谢综合征与其个体病理和氧化应激之间的关联。相关地，我们探讨了氧化应激、香烟烟雾和空气污染等主要外部来源与代谢综合征之间的相互作用，以及这种相互作用对 CAD 的影响。我们讨论了大型临床试验中抗氧化剂对心血管结局明显缺乏积极作用，并强调这些试验的一些局限性。最后，我们提供了成功使用药物抗氧化特性的证据，包括二甲双胍、他汀类药物、血管紧张素 II I 型受体阻滞剂 (ARB) 和血管紧张素 II 转换酶 (ACE) 抑制剂，用于预防和治疗代谢综合征的心血管并发症。
The metabolic syndrome affects 30% of the US population with increasing prevalence. In this paper, we explore the relationship between the metabolic syndrome and the incidence and severity of cardiovascular disease in general and coronary artery disease (CAD) in particular. Furthermore, we look at the impact of metabolic syndrome on outcomes of coronary revascularization therapies including CABG, PTCA, and coronary collateral development. We also examine the association between the metabolic syndrome and its individual component pathologies and oxidative stress. Related, we explore the interaction between the main external sources of oxidative stress, cigarette smoke and air pollution, and metabolic syndrome and the effect of this interaction on CAD. We discuss the apparent lack of positive effect of antioxidants on cardiovascular outcomes in large clinical trials with emphasis on some of the limitations of these trials. Finally, we present evidence for successful use of antioxidant properties of pharmacological agents, including metformin, statins, angiotensin II type I receptor blockers (ARBs), and angiotensin II converting enzyme (ACE) inhibitors, for prevention and treatment of the cardiovascular complications of the metabolic syndrome.